Metagenomi, Inc. Common Stock (MGX) Stock

Metagenomi, Inc. Common Stock (MGX) is a Healthcare stock trading at $1.22 (as of 2026-08-21), with a market capitalization of $46.09M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Metagenomi, Inc. is a gene editing biotechnology company developing therapeutics based on metagenomics-derived genome editing tools. It focuses on in vivo human therapeutic applications through partnerships with Moderna, and gene edited T-cell receptor-based cancer therapies with Affini-T, as well as R&D and commercialization collaborations with Ionis Pharmaceuticals.

Understand Metagenomi, Inc. Common Stock: how it makes money

Metagenomi develops gene-editing therapeutics using a metagenomics-derived genome editing toolbox, and it can monetize progress through research, development, and collaboration and license agreements, including its strategic deal with Moderna.

The company’s value creation depends on turning its metagenomics-derived genome editing toolbox into in vivo therapeutic candidates, then monetizing through collaborations and licensing (including its ModernaTX agreement).

Business quality (Weak): Early-stage biotech profile, with no reported revenue in the latest quarter and a very large operating loss, making progress on technical efficacy and safety-related readouts especially important.

Bull case

  • Platform breadth in genome editing tools: The company’s toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and CRISPR-associated transposases).
  • Strategic collaboration with ModernaTX: It has a strategic collaboration and license agreement with ModernaTX focused on new genome editing system for in vivo human therapeutic applications.

Bear case

  • No reported revenue and very large operating loss in the latest quarter: For the quarter ended 2026-03-31, revenue is reported as 0.0B and operating margin is -1970.1.
  • Efficacy and biological response vary across animal cohorts: Factor Eight activity at the 19-month time point differs by animal cohort (80.0% for Animal 1001, 10.0% for Animal 1002, 32.0% for Animal 1003), and gene integration frequency also varies across cohorts (5.3% for Animal 1001, 0.89% for Animal 1002, 2.5% for Animal 1003).
Valuation — source: SEC EDGAR (first-party)
Price$1.22
Market Cap$46.09M
Price / Book0.41
Price / Sales3.71
FCF Yield-323.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$25.21M
Net Margin-348.5%
Revenue Growth (YoY)-51.8%
EPS Growth (YoY)0.0%
FCF Growth (YoY)-20.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.07 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($2.06M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJian Irish
Employees202
CountryUS
IPO Date2006-04-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • eXoZymes, Inc. (EXOZ)
  • INmune Bio, Inc. (INMB)
  • MiNK Therapeutics, Inc. (INKT)
  • Instil Bio, Inc. (TIL)
  • Scilex Holding Company (SCLX)
  • Aligos Therapeutics, Inc. (ALGS)
  • Elutia Inc. (ELUT)
  • Quince Therapeutics, Inc. (QNCX)
MGX earnings history · MGX institutional & insider holders · MGX KPIs & operating metrics · MGX financials · MGX investor presentations & press releases · MGX SEC filings · MGX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.